KRAS p.G12C inhibitors, such as sotorasib and adagrasib, have demonstrated significant clinical efficacy, especially in KRAS G12C-mutant non-small cell lung cancer (28). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.